Biblioteca Digital da UEM: Sistema Nou-Rau
Pgina Principal  Portugus   English  Español   Aumentar Texto  Texto Normal  Diminuir Texto
  Principal | Apresentao | Objetivos | Instrues Autores | Estatsticas | Outras Bibliotecas Digitais
  Sistema Integrado de Bibliotecas - SIB / UEM
Entrar | acessos | verso 1.1  
ndice
Pgina principal
Documentos
Novidades
Usurios

Aes
Consultar
Procurar
Exibir estatsticas

Procurar por:
Procura avanada

Dvidas e sugestes


Consultar: Programa de Ps-Graduao em Cincias da Sade

Incio > Dissertaes e Teses > Cincias da Sade > Medicina > Programa de Ps-Graduao em Cincias da Sade

Ttulo [PT]: Reaes adversas decorrentes da terapia antirretroviral de alta potncia em pacientes HIV/AIDS tratados no ambulatrio DST/AIDS de Maring
Ttulo [EN]: Adverse drug reaction in hiv- infected people treated with haart in Maring, southern Brazil
Autor(es): Ione Takaki
Palavras-chave [PT]:

AIDS (doena). Sade pblica. Tratamento. HAART (Terapia antirretroviral de alta-atividade). TARV. Adverse drug reaction. Maring. Paran (Estado). Brasil.
Palavras-chave [EN]:
HIV. AIDS. HAART. Adverse drug reaction. Maring. Paran (State). Brazil.
rea de concentrao: Sade Humana
Titulao: Doutor em Cincias da Sade
Banca:
Roberto Kenji Nakamura Cuman [Orientador] - UEM
Francisco Pereria da Silva - UEL
Roberto Barboza Bazotte - UEM
Silvana Martins Caparroz Assef - UEM
Udelysses Janete Veltrini - UNING
Resumo:
Abstract: Prolonged treatment of HIV-1 disease with highly antiretroviral therapy (HAART) can be difficult to sustain because of adverse drug reactions (ADR). Knowledge of ADR of antiretroviral agents is a critical component of HIV/AIDS care and treatment. A retrospective and prospective analysis of the laboratory and clinicalepidemiological characteristics on chart review was conducted among HIV-infected patients treated with HAART between January 2010 and December 2013, from a public health Center for care and treatment in Maringa, Southern Brazil. The mean age of ART participants was 44.3 10.8 years and males and females have no age difference. The percentage of married participants were 84 (38.2%), of which 39 (46.4%) are females and 45 (53.6%) are males. Immunological and virological profile of participants was evaluated, where the mean of the first and the last CD4+ T count were 550 309 cells/μL and 642 372 cells/μL, respectively. Similarly, the mean viral load was 14,476 58,067 copies/mL and 20,828 106,028 copies/mL. The average time of ARV use is 5.6 4.2 years for all participants in this study. 28 (12.8%) participants reported having failed on adherence to medication for a period during the four years of the study. 102 patients used the therapeutic scheme based in 2 nucleoside reverse transcriptase inhibitors (NRTI) and 1 protease inhibitor (PI), wherein the ARV combination has been used lamivudine (3TC) - zidovidine (AZT) - lopinavir/ritonavir (LPV/r) (31.4%), followed by the ARV combination, 3TC-AZT- atazanavir/ritonavir (ATV/r) (28.4%). The therapeutic scheme 2 NRTI and 1 nonnucleoside reverse transcriptase inhibitors (NNRTI) was used for 79 patients, with the ARV combination was 3TC-AZT- efavirenz (EFZ) (65.8%). Gastrointestinal disorders (25.9%), neuropychiatric symptoms (18.2%) and hypertension (25.4%) are the changes more often presented by patients during the study period. ADRs that presented a greater number of participants were: anemia (48.8%), hypertriglyceridemia (47.3%), hypercholesterolemia (36.1%) and hyperglycemia (22.6%). 38 (17.3%) participants had opportunistic disease and lipodystrophia was observed in 11 (5.0%). The study demonstrated ADRs in HIV-infected patients treat in a public health Center for care and treatment in Maringa. Southern Brazil.
Data da defesa: 29/02/2016
Cdigo: vtls000223639
Informaes adicionais:
Idioma: mul
Data de Publicao: 2016
Local de Publicao: Maring, PR
Orientador: Prof. Dr. Roberto Kenji Nakamura Cuman
Instituio: Universidade Estadual de Maring . Centro de Cincias da Sade
Nvel: Tese (doutorado em Cincias da Sade)
UEM: Programa de Ps-Graduao em Cincias da Sade

Responsavel: edson
Categoria: Aplicao
Formato: Documento PDF
Arquivo: defesa final 30 09 16.pdf
Tamanho: 695 Kb (712104 bytes)
Criado: 30-05-2017 21:02
Atualizado: 30-05-2017 21:10
Visitas: 266
Downloads: 2

[Visualizar]  [Download]

Todo material disponvel neste sistema de propriedade e responsabilidade de seus autores.